1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester manufacturers
- R-10015
-
- $48.00
-
2026-07-14
- CAS:2097938-51-5
- Purity: 98.97%
- Supply Ability: 10g
- R-10015
-
- $48.00
-
2026-07-14
- CAS:2097938-51-5
- Purity: 98.97%
- Supply Ability: 10g
|
| | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Basic information |
| Product Name: | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester | | Synonyms: | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester;Methyl 2-(1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxylate;methyl 2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-1H-benzo[d]imidazole-6-carboxylate;Methyl 2-(1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-1H-benzo[d]imidazole-6-carboxylate;R-10015,inhibit,R10015,Inhibitor,LIMKs,Reverse Transcriptase,LIM Kinase (LIMK),R 10015;R-10015, 10 mM in DMSO | | CAS: | 2097938-51-5 | | MF: | C20H19ClN6O2 | | MW: | 410.86 | | EINECS: | | | Product Categories: | | | Mol File: | 2097938-51-5.mol | ![1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Structure](CAS/20200331/GIF/2097938-51-5.gif) |
| | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Chemical Properties |
| density | 1.465±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 62.5 mg/mL (152.12 mM; Need ultrasonic) | | form | Solid | | pka | 10.68±0.10(Predicted) | | color | Off-white to pink |
| | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Usage And Synthesis |
| Uses | R-10015, a broad-spectrum antiviral compound for HIV infection, acts as a potent and selective inhibitor of LIM domain kinase (LIMK) and binds to the ATP-binding pocket, with an IC50 of 38 nM for human LIMK1[1]. | | Biological Activity | R-10015 is a potent and selective LIM domain kinase (LIMK) inhibitor with IC50 of 38 nM for human LIMK1. It binds to the ATP-binding pocket and acts as a broad-spectrum antiviral compound for HIV infection. | | in vitro | R-10015 (100 μM; 0-4 hours) inhibits cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells.
R-10015 inhibits HIV-1 DNA synthesis, nuclear migration, and virion release.
R-10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1) .< br/> Western Blot Analysis | Cell Line: | CEM-SS T cells | | Concentration: | 100 μM | | Incubation Time: | 0 hour,0.5 hour,1 hour,2 hours,4 hours | < td class="col1"> Result: | Inhibited cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells. | | | in vivo | R-10015 (10 mg/kg; ip) displays no indication of toxicity. The result suggests the possibility of short-term use of LIMK inhibitors to block viral infections.
< p> | Animal Model: | 6-8 weeks female C3H/HeN mice | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Displayed none indication of toxicity. | < /tr> | | target | | Target | Value | hLIMK1
(Cell-free assay) | 38 nM |
| | IC 50 | human LIMK1: 38 nM (IC50) | | References | [1] Yi F, et al. Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. J Virol. 2017 Jun 9;91(13). pii: e02418-16. DOI:10.1128/JVI.02418-16 |
| | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Preparation Products And Raw materials |
|